-+ 0.00%
-+ 0.00%
-+ 0.00%

Cellectar Biosciences FY 2024 GAAP EPS $(1.40) Beats $(1.59) Estimate

Benzinga·03/13/2025 11:03:26
Listen to the news
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(1.40) per share which beat the analyst consensus estimate of $(1.59) by 11.95 percent. This is a 60 percent increase over losses of $(3.50) per share from the same period last year.